A detailed history of Black Rock Inc. transactions in Reneo Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 293,651 shares of RPHM stock, worth $493,333. This represents 0.0% of its overall portfolio holdings.

Number of Shares
293,651
Previous 993,659 70.45%
Holding current value
$493,333
Previous $1.65 Million 73.14%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$1.51 - $1.9 $1.06 Million - $1.33 Million
-700,008 Reduced 70.45%
293,651 $443,000
Q1 2024

May 10, 2024

BUY
$1.59 - $1.74 $16,464 - $18,017
10,355 Added 1.05%
993,659 $1.65 Million
Q4 2023

Feb 13, 2024

BUY
$1.34 - $8.43 $488,408 - $3.07 Million
364,484 Added 58.9%
983,304 $1.57 Million
Q3 2023

Nov 13, 2023

BUY
$5.44 - $8.13 $880,708 - $1.32 Million
161,895 Added 35.43%
618,820 $4.72 Million
Q2 2023

Aug 11, 2023

BUY
$5.44 - $10.5 $2.36 Million - $4.55 Million
433,288 Added 1833.09%
456,925 $3 Million
Q1 2023

May 12, 2023

SELL
$2.44 - $6.42 $1,625 - $4,275
-666 Reduced 2.74%
23,637 $141,000
Q4 2022

Feb 13, 2023

BUY
$1.8 - $3.52 $900 - $1,760
500 Added 2.1%
24,303 $56,000
Q3 2022

Nov 14, 2022

BUY
$2.35 - $4.85 $1,858 - $3,836
791 Added 3.44%
23,803 $80,000
Q2 2022

Aug 12, 2022

SELL
$1.96 - $3.04 $576,269 - $893,805
-294,015 Reduced 92.74%
23,012 $61,000
Q1 2022

May 12, 2022

BUY
$2.94 - $9.07 $446 - $1,378
152 Added 0.05%
317,027 $932,000
Q4 2021

Feb 10, 2022

BUY
$6.07 - $9.68 $137,145 - $218,709
22,594 Added 7.68%
316,875 $2.71 Million
Q3 2021

Nov 09, 2021

BUY
$6.28 - $11.07 $27,989 - $49,338
4,457 Added 1.54%
294,281 $2.19 Million
Q2 2021

Aug 11, 2021

BUY
$7.78 - $15.0 $2.25 Million - $4.35 Million
289,824 New
289,824 $2.7 Million

Others Institutions Holding RPHM

About Reneo Pharmaceuticals, Inc.


  • Ticker RPHM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,479,600
  • Market Cap $41.1M
  • Description
  • Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as w...
More about RPHM
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.